Evidence map›Paper›PMID 36756286›Full record

ArticleBMJ open sport & exercise medicine2023

ELITE: rationale and design of a longitudinal elite athlete, extreme cardiovascular phenotyping, prospective cohort study.

Juliette C van Hattum, Sjoerd M Verwijs, S Matthijs Boekholdt, Maarten Groenink, R Nils Planken, Adrienne van Randen, Aart J Nederveen, Maarten H Moen, Cornelis A C M Wijne, Joelle J N Daems and 9 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open sport & exercise medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Human whole-blood NADNature metabolism · 2026
    Article
  2. Article
  3. Native T1 mapping times are strongly influenced by elite athlete status.European heart journal. Cardiovascular Imaging · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 1 country.

Juliette C van HattumCardiology, UMC location University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.ORCID 0000-0003-0168-7783
Sjoerd M VerwijsCardiology, UMC location University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.ORCID 0000-0003-3785-4985
S Matthijs BoekholdtCardiology, UMC location University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.ORCID 0000-0002-0861-0765
Maarten GroeninkCardiology, UMC location University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
R Nils PlankenRadiology and Nuclear Medicine, Amsterdam UMC location University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.ORCID 0000-0003-3940-4670
Adrienne van RandenRadiology and Nuclear Medicine, Amsterdam UMC location University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
Aart J NederveenRadiology and Nuclear Medicine, Amsterdam UMC location University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
Maarten H MoenDutch National Olympic Committee & National Sports Federation, High-Performance Team, Arnhem, The Netherlands.
Cornelis A C M WijneSports Physicians, OLVG Location West, Amsterdam, The Netherlands.
Joelle J N DaemsCardiology, UMC location University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
Birgitta K VelthuisRadiology, UMC Utrecht, University of Utrecht, Utrecht, The Netherlands.ORCID 0000-0002-2542-9474
Danny A J van de SandeCardiology, UMC Utrecht, University of Utrecht, Utrecht, The Netherlands.
Ruud SpeeCardiology, Maxima Medical Center, Veldhoven, The Netherlands.
Suzanna T de VriesCardiology, Hospital Tjongerschans, Heerenveen, The Netherlands.
Maurits J van der VeenCardiology, Hospital Gelderse Vallei, Ede, The Netherlands.
Yigal M PintoCardiology, UMC location University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
Arthur A M WildeCardiology, UMC location University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
Harald T JorstadCardiology, UMC location University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.ORCID 0000-0003-3617-3256
ELITE Consortium
Amsterdam University Medical Centers · NLUtrecht University · NLNederlands Olympisch Comité Nederlandse Sport Federatie · NLRadboud University Nijmegen · NL's Heeren Loo · NLZiekenhuis Gelderse Vallei · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The cardiovascular benefits of physical exercise are well-known. However, vigorous exercise has also been associated with adverse cardiac effects. To improve our understanding of cardiovascular adaptation to exercise versus maladaptation and pathology, the limits of adaptation should be firmly established using state-of-the-art diagnostic modalities. We therefore initiated the Evaluation of Lifetime participation in Intensive Top-level sports and Exercise (ELITE) cohort to investigate the longitudinal (beneficial and pathological) cardiovascular effects of intensive elite sports and exercise. Methods and analysis: ELITE is a prospective, multicentre, longitudinal cohort study. Elite athletes, from the age of sixteen, are recruited in The Netherlands. The primary objective is to determine the association between elite sports and exercise-induced cardiac remodelling, cardiac pathology, and health benefits over time. Secondary objectives include determining and identifying genetic profiles of elite athletes, and how these are associated with cardiac indices. ELITE will collect data from consultations, electrocardiography, echocardiography and cardiac magnetic resonance imaging, and training- and injury data. ELITE will also collect blood for biobanking and cardiogenetics. Follow-up will take place at intervals of two to five years, and after the elite athletes' professional careers have ended. In addition, a subcohort of ELITE has been established to investigate cardiac sequelae following infections associated with myocardial involvement, including SARS-CoV-2. ELITE is a prospective observational study; therefore, analyses will be primarily explorative. Ethics and dissemination: This study has been approved by the Medical Ethics Review Board of the Amsterdam University Medical Centers (NL71682.018.19). The results of the study will be disseminated by publication in peer-reviewed journals (Netherlands Trial Register number: NL9328).

Indexed as

AthleteCardiology preventionElite performanceProspectiveSports & exercise medicine

Identifiers

PMID36756286
PMCPMC9900067
OpenAlexW4319078652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.